Clinical Trial Data on Ozempic and Sexual Function
In the phase 3 SUSTAIN clinical program for semaglutide, sexual dysfunction was reported as an adverse event in a small percentage of participants, with rates generally similar to placebo in many trials. The prescribing information for Ozempic lists decreased libido and erectile dysfunction as possible side effects based on clinical trial data and post-marketing reports. The U.S. Food and Drug Administration (FDA) approved Ozempic (semaglutide) for type 2 diabetes in 2017, and the label includes warnings and precautions about potential effects on sexual function, as documented in the FDA label and medical resources such as the Mayo Clinic overview of semaglutide. For the most current prescribing details, see the official Ozempic prescribing information on the Novo Nordisk website at https://www.novonordisk.com.
Meta-analyses and systematic reviews of GLP-1 receptor agonists, including semaglutide, have noted that gastrointestinal side effects are the most common, while sexual dysfunction is reported less frequently but remains a recognized potential adverse effect. Regulatory databases such as the FDA Adverse Event Reporting System (FAERS) collect post-marketing reports of sexual side effects, and these reports contribute to the safety profile listed in the label. Clinical guidance from organizations such as the American Diabetes Association notes that patients should be informed about potential sexual side effects when starting GLP-1 receptor agonist therapy, as highlighted in standards of care documents and resources like the Endocrine Society's clinical guidelines.
Reported Effects on Libido and Sexual Performance
Decreased Libido and Other Sexual Side Effects
Post-marketing reports and patient discussions indicate that some individuals using Ozempic have experienced decreased libido, difficulty with arousal, or reduced sexual satisfaction, though these experiences vary widely across users. Weight loss associated with Ozempic can also influence body image and psychological factors that may indirectly affect sexual desire and performance, as noted in reviews on sexual health and metabolic medication effects. The manufacturer, Novo Nordisk, includes decreased libido and other sexual dysfunction events in the post-marketing experience section of the Ozempic label, based on voluntary reports from users since the drug's approval.
Erectile Dysfunction and Other Performance Issues
Erectile dysfunction has been reported by some male users of Ozempic, and it is listed in the post-marketing experience section of the prescribing information, though a direct causal relationship in all cases has not been established in large-scale trials. Clinical studies on GLP-1 receptor agonists have shown mixed results, with some research suggesting potential cardiovascular and metabolic benefits that could improve certain aspects of sexual health over time, while other users report new or worsening sexual difficulties. Healthcare providers are advised to ask about sexual side effects during follow-up visits, and patients are encouraged to report any new or worsening symptoms to their prescriber or to the FDA MedWatch program at https://www.fda.gov.
User Experiences, Comparisons, and Clinical Guidance
Patient Reports and Real-World Data
Online patient forums and real-world survey data show a range of experiences, with some users reporting no change in sex drive, others noting improvement due to weight loss and metabolic health gains, and a subset reporting decreased libido or sexual side effects after starting Ozempic. Real-world evidence complements clinical trial data, and ongoing pharmacovigilance by Novo Nordisk and regulatory agencies helps to update the known safety profile as more patients use the medication in diverse populations and health contexts.
Clinical Guidance and When to Seek Help
Clinical guidelines recommend that patients